ProCE Banner Activity

ALGONQUIN Part 1: Phase I Trial of Belantamab Mafodotin With Pomalidomide/Dexamethasone in Patients With R/R Multiple Myeloma

Slideset Download
Conference Coverage
Combination of belantamab mafodotin with pomalidomide/dexamethasone resulted in high response rates in patients with relapsed/refractory multiple myeloma.

Released: December 08, 2020

Expiration: December 07, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology